Spontaneous Tumours in Guinea Pigs
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Heart Tumors in Domestic Animals
HEART TUMORS IN DOMESTIC ANIMALS Marko Hohšteter Department of veterinary pathology, Veterinary Faculty University of Zagreb Neoplasms of the heart are rare diseases in domestic animals. Among all domestic animals heart neoplasm are most common in dogs. Most of the canine heart tumors are primary what is contrary to other domestic animals, in which most of cardiac tumors are metastatic. Primary tumors of the heart represent 0,69% of the canine tumors. Among all primary neoplasms canine hemangiosarcoma of the right atrium is the most common. Other primary cardiac tumors in domestic animals include rhabdomyoma, rhabdomyosarcoma, myxoma, myxosarcoma, chondrosarcoma, osteosarcoma, granular cell tumor, fibroma, fibrosarcoma, lipoma, pericardial mesothelioma and undifferentiated sarcoma. Aortic and carotid body tumors are usually classified under primary heart neoplasm but are actually tumors which arise in adventitia or periarterial adipose tissue of the aorta, carotid artery or pulmonary artery, and can extend to heart base. Hemangiosarcoma is the most important and most frequent cardiac neoplasm of dogs. This tumor develops primary from the blood vessels that line the heart or can matastasize from sites such as spleen, skin or liver. It is most commonly reported in mid to large breeds, such as boxers, German shepherds, golden retrievers, and in older dogs (six years and older). Aortic and carotide body adenoma and adenocarcinoma belong into the group of chemoreceptor tumors („chemodectomas“) and are morphologicaly similar. In animals, incidence of aortic body neoplasm is higher than that of the carotide body. Both tumors mostly develop in dogs (brachyocephalic breed: boxers, Boston teriers), and are rare in cats and cattle. -
PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information. -
第32回日本皮膚病理組織学会学術大会 診断投票結果 口演 1 Drug Eruption 13, うち Erythema Multif
第32回日本皮膚病理組織学会学術大会 診断投票結果 口演 1 Drug eruption 13, うち erythema multiforme 1, Interface dermatitis 1, GVHD type 1 Cutaneous reaction due to CCR4 3, うち Dysplastic epidermal hyperplasia 2, Adverse reaction 1 Erythema multiforme 3 PLEVA 1 Vacuolar type interface dermatitis 1 口演 2 Syringofibroadenoma 15, うち + amyloid 1 Syringofibroadenoma with BCC 5 Basal cell carcinoma 4, うち Pinkus type of BCC with syringofibroadenoma 2 口演 3 Darier disease 5 Hailey-Hailey disease 4 Pemphigus 3, うち Pemphigus Vegetans 1, Neonatal pemphigus 1 Grover's disease 4 Epidermal nevus 5, うち Acantholytic (dyskeratotic) epidermal nevus 4, Linear epidermal nevus 1 口演 4 Hydradenoma 13, うち Clear cell hidradenoma 12, Nodular hidradenoma 1 Sebaceous adenoma 1 Trichilemmoma 1 Metastatic tumor 8, うち ~ renal carcinoma6, ~ Clear cell carcinoma 2 口演 5 Apocrine carcinoma 3, うち ~with pagetoid spreading 2 Ectopic breast carcinoma(invasive ductal type)with pagetoid phenomenon 2 Extramammary Paget's disease 12, うち Paget carcinoma 3, ~ with Apocrine adenoma 2, ~ with Tubular adenoma 1, Invasive ~ 1, +Skin metastasis 1, With syringoma 1, with Microcystic Adnexal Carcinoma 1 Syringomatous carcinoma 2, うち ~with paget phenomenon 1 Tubular adenocartinoma 1 Tubular (apocrine) adenoma 2 Syringoma 1 口演 6 Dermatofibroma 10, うち Lipidized ~ 3, Hemosiderotic deep cellular ~ 2, Xanthomatous ~ 1, ~ Histiocytoid variant 1 Fibous histiocytoma 8, うち Atypical ~ 3, Malignant ~ 2, Aneurismal ~ 2 Undifferentiated pleomorphic sarcoma 2 Progressive nodular histiocytosis 1 Squamous -
Partners in Care – January 2017
The newSEE CE Schedule INSIDE & on a Referralremovable Contact postcard! Info Partners In Care Veterinary Referral News from Angell Animal Medical Center Winter 2017 π Volume 11:1 π angell.org π facebook.com/AngellReferringVeterinarians PRE-HOSPITAL EYELID MARGIN SEDATION OPTIONS BUILDING A RADIOGRAPHIC TUMOR GRADING— MASSES IN DOGS: FOR AGGRESSIVE AND CONFIDENT PUPPY APPROACH TO IS IT APPLICABLE? TO CUT OR ANXIOUS DOGS BONE IMAGING NOT TO CUT? PAGE 1 PAGE 1 PAGE 4 PAGE 6 PAGE 8 ANESTHESIA BEHAVIOR Pre-Hospital Sedation Building a Options for Aggressive Confident Puppy and Anxious Dogs π Terri Bright, Ph.D., BCBA-D, CAAB π Kate Cummings, DVM, DACVAA angell.org/behavior [email protected] angell.org/anesthesia 617-989-1520 [email protected] 617-541-5048 ggressive and/or fearful dogs present several challenges for the othing makes everyone happier than having puppies in the small animal practitioner. These patients are difficult to fully veterinary office. The client brings the pup soon after they evaluate and present a safety hazard to the clinic staff, purchase or adopt it to make sure it is healthy, and to begin the veterinarian, and sometimes even the owner. In addition, a process of vaccinations and a lifetime of health. Everyone oohs Anervous dog contributes to heightened stress within the work area affecting Nand ahs over it, but what are the most important things a vet and their staff not only people, but other pets alike. In dogs known to be aggressive within can do to make sure the pup grows up to be happy and behaviorally healthy? the hospital setting or those with tremendous fear/anxiety, making physical exams and basic assessment impossible, pre-hospital sedation can First, find out what the puppy’s history is. -
Evidenzbericht: S3-Leitlinie „Adulte Weichgewebesarkome“
Institut für Forschung in der Operativen Medizin (IFOM) Evidenzbericht: S3-Leitlinie „Adulte Weichgewebesarkome“ IFOM - Institut für Forschung in der Operativen Medizin (Universität Witten/Herdecke) Jessica Breuing, Tim Mathes, Katharina Doni, Tanja Rombey, Barbara Prediger, Dawid Pieper Datum: 03.07.2020 Kontakt: Jessica Breuing IFOM - Institut für Forschung in der Operativen Medizin Univ.-Prof. Dr. Rolf Lefering Fakultät für Gesundheit, Department für Humanmedizin Universität Witten/Herdecke Ostmerheimer Str. 200, Haus 38 51109 Köln Tel.: 0221 98957-41 Fax: 0221 98957-30 Dr. Tim Mathes IFOM - Institut für Forschung in der Operativen Medizin Univ.-Prof. Dr. Rolf Lefering Fakultät für Gesundheit, Department für Humanmedizin Universität Witten/Herdecke Ostmerheimer Str. 200, Haus 38 51109 Köln Tel.: 0221 98957-43 Fax: 0221 98957-30 Inhalt 1. Literaturrecherche ........................................................................................................................ 5 1.1. Einschlusskriterien Systemtherapie ....................................................................................... 5 1.1.1. Neoadjuvante Systemtherapie (+ GIST) ........................................................................ 5 1.1.2. Adjuvante Systemtherapie (+ GIST) ............................................................................... 5 1.1.3. Therapie der metastasierten Erkrankung (+ GIST) ...................................................... 6 1.2. Einschlusskriterien Chirurgie .................................................................................................. -
A Clinico-Histopathological Study of Cutaneous Appendageal Tumours
IP Indian Journal of Clinical and Experimental Dermatology 5 (2019) 206–210 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article A clinico-histopathological study of cutaneous appendageal tumours Gowda Monika M1, S Sathish K1, M Basavarajaiah D2,* 1Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India 2Dept. of Dermatology, KVAFSU B Hebbal, Bidar, Karnataka, India ARTICLEINFO ABSTRACT Article history: The cutaneous appendageal tumors are an ideal subject for study from clinical and morphological point Received 01-08-2019 of view and so ubiquitous that they can affect people of all age group A histopathological study of 100 Accepted 13-08-2019 cases of cutaneous appendageal tumors was carried out at tertiary care hospital over 18 months. A Total Available online 14-09-2019 95 cases were benign and 5 cases were malignant tumors, constituting 95.0 % p<0.01 and 5.0 % p>0.01 respectively. Sweat gland tumors were the most common manifestation (79.0% ) p<0.01, followed by hair follicle tumors (20%) and eccrine duct tumors 1(1%). Male and female ratio was 27:73. The commonest Keywords: affected body site was head and neck region . The mean age was 36.58 1.22 years . Out of 95 cases cutaneous appendageal tumors of benign tumors, syringoma accounted for 48% (48), trichoepithelioma12 p<0.01, eccrine hydrocystoma malignant (11) p<0.01 ,trichofolliculoma, Apocrine hydrocystoma and nodular hidradenomaeach (4)p>0.01. Total histopathologically (39) p<0.01 are correlating both clinically and histopathologically and (61) p<0.01 are not correlating clinically clinically and histopathologically. -
Adnexal Tumors
10/24/2019 What’s a gland like you doing in a place like this? A practical approach to cutaneous adnexal neoplasms Hafeez Diwan, MD, PhD Departments of Pathology & Immunology and Dermatology Baylor College of Medicine 1 Conflict of interest • None 2 Disclosures • I have nothing to disclose 3 1 10/24/2019 Is the adnexal neoplasm glandular? And if so, where is it located? • Hands and Feet: Digital papillary adenocarcinoma 4 5 6 2 10/24/2019 7 8 Digital Papillary Adenocarcinoma • Solitary • Fingers/toes/palms/soles • Recurrence/metastases 9 3 10/24/2019 10 11 12 4 10/24/2019 3 Points about digital papillary adenocarcinoma • 1. Atypia doesn’t matter – if there is no atypia, it doesn’t mean that it isn’t digital papillary adenocarcinoma 13 3 Points about digital papillary adenocarcinoma • 1. Atypia doesn’t matter – if there is no atypia, it doesn’t mean that it isn’t digital papillary adenocarcinoma • 2. How high can the glandular lesion go up the extremity? • Example of one case that occurred on the thigh? (Alomari A, Douglas S, Galan A, Narayan D, Ko C. Atypical Presentation of digital papillary adenocarcinoma (abstract) J Cutan Pathol. 2014;41:221) 14 3 Points about digital papillary adenocarcinoma (cont’d) • 3. What if you don’t see glands • Hidradenoma on hands and feet • Hunt for a gland? If you see a gland, then what? • Probably best to err on the side of caution and say that a digital papillary adenocarcinoma is not ruled out 15 5 10/24/2019 16 17 18 6 10/24/2019 19 20 21 7 10/24/2019 3 Points about digital papillary adenocarcinoma (cont’d) • 3. -
Dermatopathology
Dermatopathology Clay Cockerell • Martin C. Mihm Jr. • Brian J. Hall Cary Chisholm • Chad Jessup • Margaret Merola With contributions from: Jerad M. Gardner • Talley Whang Dermatopathology Clinicopathological Correlations Clay Cockerell Cary Chisholm Department of Dermatology Department of Pathology and Dermatopathology University of Texas Southwestern Medical Center Central Texas Pathology Laboratory Dallas , TX Waco , TX USA USA Martin C. Mihm Jr. Chad Jessup Department of Dermatology Department of Dermatology Brigham and Women’s Hospital Tufts Medical Center Boston , MA Boston , MA USA USA Brian J. Hall Margaret Merola Department of Dermatology Department of Pathology University of Texas Southwestern Medical Center Brigham and Women’s Hospital Dallas , TX Boston , MA USA USA With contributions from: Jerad M. Gardner Talley Whang Department of Pathology and Dermatology Harvard Vanguard Medical Associates University of Arkansas for Medical Sciences Boston, MA Little Rock, AR USA USA ISBN 978-1-4471-5447-1 ISBN 978-1-4471-5448-8 (eBook) DOI 10.1007/978-1-4471-5448-8 Springer London Heidelberg New York Dordrecht Library of Congress Control Number: 2013956345 © Springer-Verlag London 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. -
New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml. -
Bone and Soft Tissue Sarcomas
Bone and Soft Tissue Sarcomas Changes to Pathology Codes in the 4th Edition of the World Health Organisation Classification of Bone and Soft Tissue Sarcomas September 2013 Page 1 of 17 Authors Mr Matthew Francis Cancer Analysis Development Manager, Public Health England Knowledge & Intelligence Team (West Midlands) Dr Nicola Dennis Sarcoma Analyst, Public Health England Knowledge & Intelligence Team (West Midlands) Ms Jackie Charman Cancer Data Development Analyst Public Health England Knowledge & Intelligence Team (West Midlands) Dr Gill Lawrence Breast and Sarcoma Cancer Analysis Specialist, Public Health England Knowledge & Intelligence Team (West Midlands) Professor Rob Grimer Consultant Orthopaedic Oncologist The Royal Orthopaedic Hospital NHS Foundation Trust For any enquiries regarding the information in this report please contact: Mr Matthew Francis Public Health England Knowledge & Intelligence Team (West Midlands) Public Health Building The University of Birmingham Birmingham B15 2TT Tel: 0121 414 7717 Fax: 0121 414 7712 E-mail: [email protected] Acknowledgements The Public Health England Knowledge & Intelligence Team (West Midlands) would like to thank the following people for their valuable contributions to this report: Dr Chas Mangham Consultant Orthopaedic Pathologist, Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust Professor Nick Athanasou Professor of Musculoskeletal Pathology, University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Copyright @ PHE Knowledge & Intelligence Team (West Midlands) 2013 1.0 EXECUTIVE SUMMARY Page 2 of 17 The 4th edition of the World Health Organisation (WHO) Classification of Tumours of Soft Tissue and Bone which was published in 2012 contains notable changes from the 2002 3rd edition. The key differences between the 3rd and 4th editions can be seen in Table 1. -
Canine Myxosarcomas, a Retrospective Analysis of 32 Dogs (2003–2018) Yoshimi Iwaki1* , Stephanie Lindley1, Annette Smith1, Kaitlin M
Iwaki et al. BMC Veterinary Research (2019) 15:217 https://doi.org/10.1186/s12917-019-1956-z RESEARCH ARTICLE Open Access Canine myxosarcomas, a retrospective analysis of 32 dogs (2003–2018) Yoshimi Iwaki1* , Stephanie Lindley1, Annette Smith1, Kaitlin M. Curran2 and Jayme Looper3 Abstract Background: Myxosarcomas are known to be classified as soft tissue sarcomas. However, there is limited clinical characterization pertaining specifically to canine cutaneous myxosarcomas in the literature. The objective of this study is to evaluate the local recurrence rate, metastatic rate and prognosis of canine myxosarcoma. Results: A total of 32 dogs diagnosed with myxosarcoma via histopathology were included in this retrospective study. All dogs had surgical resection. No adjunct treatments were performed in 9 dogs, while 22 dogs also received either radiation therapy or chemotherapy, or a combination of both. One dog received only NSAID after surgery. Overall median survival time (MST) was 730 days (range 20–2345 days). The MST of dogs with a tumor mitotic count < 10/10 HPF was 1393 days (range 20–2345 days). The dogs with a tumor mitotic count of 10 or greater/10 HPF had a MST of 433 days (range 169–831 days). There was no significant difference of MST among different treatment modalities. Local recurrence was noted in 13 cases (40.6%) and the median time to recurrence was 115.5 days (range 50–1610 days). The median time to local recurrence in dogs with mitotic count of < 10/10 HPF was 339 days (range 68–1610 days) and in dogs with mitotic count of 10 or greater/10 HPF was 119 days (range 50–378). -
Ultra-Rare Cystic Disease
SERIES ULTRA-RARE LUNG DISEASE Ultra-rare cystic disease Davide Elia1, Olga Torre1, Roberto Cassandro1, Antonella Caminati1 and Sergio Harari 1,2,3 Number 2 in the Series “Ultra-rare lung disease” Edited by Sergio Harari and Marc Humbert Affiliations: 1U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - MultiMedica IRCCS, Milan, Italy. 2Dept of Medical Sciences San Giuseppe Hospital MultiMedica IRCCS, Milan, Italy. 3Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Correspondence: Roberto Cassandro. U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - MultiMedica IRCCS, Via San Vittore 12, 20123 Milan, Italy. E-mail: [email protected] @ERSpublications Diffuse cystic lung diseases show a characteristic CT scan pattern that often allows for diagnosis, even in asymptomatic patients, allowing prompt correct therapy and management without the needing of a biopsy https://bit.ly/2wIUKet Cite this article as: Elia D, Torre O, Cassandro R, et al. Ultra-rare cystic disease. Eur Respir Rev 2020; 29: 190163 [https://doi.org/10.1183/16000617.0163-2019]. ABSTRACT Diffuse cystic lung diseases include a group of heterogeneous disorders characterised by the presence of cysts within the lung parenchyma, sometimes showing a characteristic computed tomography scan pattern that allows diagnosis. The pathogenetic mechanisms underlying cyst formation in the lung are still not clear and a number of hypotheses have been postulated according to the different aetiologies: ball-valve effect, ischaemic dilatation of small airways and alveoli related to infiltration and obstruction of small vessels and capillaries that supply the terminal bronchioles and connective tissue degradation by matrix metalloproteases.